Research and Markets - Global Opportunities in Development of Molecular diagnostics Analysed

Research and Markets has announced the addition of the revised edition of "Molecular Diagnostics: Transforming Pharmaceuticals, Impacting New Markets" to their offering.

(PRWEB) October 20, 2004 -- Research and Markets has announced the addition of the revised edition of "Molecular Diagnostics: Transforming Pharmaceuticals, Impacting New Markets" to their offering.

The in vitro diagnostics industry is at the forefront of far-reaching changes in healthcare. Based on a deeper understanding of the molecular basis of disease and individual differences in disease susceptibility and drug responses, molecular diagnostics will enable selection of the most effective treatment for each individual patient, initiation of treatment at an early or presymptomatic stage, and in some cases, prevention of disease altogether.

This Report brings the reader up-to-date on all the intervening developments in the areas of nucleic acid testing and specialist immunoassays, and, in addition, covers a much wider range of platform technologies and products. There are new sections on topics such as DNA microarrays, gene expression profiling, protein chips, protein expression profiling, lipidomics, and bioinformatics.

The Report offers coverage of all major disease areas with an emphasis on the biggest and growing markets. In addition, expanding applications of molecular diagnostics outside the clinical field are surveyed - including veterinary, food and water testing, and anti-counterfeiting applications. Molecular diagnostics opportunities within the top eight world markets are discussed, and profiles of key companies currently developing molecular diagnostics are included.

Market Opportunities

- Develop new diagnostic and predictive tests by exploiting recent technology advances in molecular analysis.

- Create safer, more effective personalized treatments through the development of targeted therapies that rely upon more specific markers of disease and drug responsivenss.

- Discover and develop novel companion diagnostic-drug products by capitalizing on discoveries of new molecular markers of disease and creating synergy between diagnostic and pharmaceutical industries.

This report will enable readers to:

- Pinpoint the full market potential of molecular diagnostics with a comprehensive examination of high-growth applications, including the biggest and most rapidly expanding therapeutic markets - communicable diseases, cardiology, and oncology.

- Gain insight into the non-clinical field of molecular diagnostics through a complete review of non-clinical applications, including veterinary, food and water, and anti-counterfeiting.

- Identify viable technology drivers through a comprehensive look at various platform technologies for molecular diagnostics.

- Obtain a thorough understanding of the chief molecular diagnostic tests available - predictive, screening, prognostic, monitoring, theranostic - from an extensive study of their basic principles to their applications.

- Learn about global industry developments through an in-depth analysis of the major world markets for molecular diagnostics, including forecasts for growth.

- Look inside 30 companies working within molecular diagnostics, including their products and services, financial standing, M&A activity, research pipelines, and more.

Contents Include:

- Technology Developments

- Communicable Diseases

- Cardiovascular Diseases.

- Cancer

- Miscellaneous Diseases and Conditions

- Non-Clinical Applications

- Company Profiles

- Trends and Opportunities

Company Profiles included in this report

-    Abbott Laboratories Inc

-    Agendia BV

-    Bayer AG

-    Biosite Inc

-    Cepheid

-    Chembio Diagnostic Systems Inc

-    Chiron Corporation

-    Ciphergen Biosystems Inc

-    Correlogic Systems

-    Diagnostic Products Corporation

-    DiagnoSwiss SA

-    Digene Corporation

-    Epigenomics AG

-    EXACT Sciences Corp

-    Genaissance Pharmaceuticals Inc

-    Gen-Probe Inc

-    HandyLab

-    Innogenetics NV

-    Interleukin Genetics

-    Matritech Inc

-    Myriad Genetics Inc

-    Nanogen

-    Nuvelo Inc

-    Nymox Pharmaceutical Corp

-    OXIS International Inc

-    Proteome Sciences plc

-    Roche Holding Ltd

-    Sequenom Inc

-    SomaLogic Inc

-    Third Wave Technologies Inc

For more information visit http://www.researchandmarkets.com/reports/c7600

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

###